Back

10-year trends in the use of catheter ablation for the treatment ofVT versus other ablation procedures and PCI for the treatment of IHD

17 March 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2019

About the speaker

Photo
Doctor Robert Anderson

Toronto General Hospital, Toronto (Canada)

18 More presentations in this session

Presentation thumbnail
Association between ventricular fibrillation recurrences and chest compressions in out-of-hospital cardiac arrest
Associate Professor F. Guerra (Ancona, IT)
Abstract
Presentation thumbnail
Clinical impact on ventricular arrhythmic risk of serum free thyroxine concentration in euthyroid patients with structural heart diseases
Associate Professor H. Makimoto (Shimotsuke, JP)
Abstract
Presentation thumbnail
Precedent non-sustained ventricular tachycardias predicts subsequent ICD interventions and heart failure hospitalization in primary prevention ICD patients
Associate Professor H. Makimoto (Shimotsuke, JP)
Abstract
Presentation thumbnail
P-wave morphology and risk of sudden cardiac death in patients with coronary artery disease
Doctor J. Perkiomaki (Oulu, FI)
Abstract
Presentation thumbnail
First comprehensive clinical and genetic characterization of patients with cardiac channelopathies and unexplained aborted sudden cardiac death in the sardinian population
Doctor P. Berne (Sassari, IT)
Abstract

Access the full session

Session thumbnail
Poster session 3 - Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome

The Event

Event poster

EHRA 2019

17 March - 19 March 2019
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources